Dr. John Mendelsohn, Chairman, Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine
“Our mission is to rapidly translate personalized cancer medicine discoveries into standards of patient care worldwide.” Dr. John Mendelsohn, Chairman, Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine

WINning together

WIN was formed on the premise that we can accomplish more together than each organization can achieve working alone. We aim to improve cancer patients’ survival and quality of life. View WIN's history and unique attributes:

WIN represents a global collaboration of cancer centers, life science and biotech organizations, pharmaceutical and technology companies, health plans, and not-for-profit organizations.
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine was initiated in 2010 with leadership from leading cancer centers worldwide. WIN is a non-profit, non-governmental organization headquartered in Paris.

WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.

WIN now includes 35 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.

Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
WIN is comprised of organizations representing all stakeholders in personalized cancer medicine.
WIN enables cross-sector collaborations designed to accelerate the speed and efficacy with which breakthroughs in personalized cancer medicine can be realized and brought to patients worldwide.

Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
Our members include 25 leading academic centers representing 17 countries and four continents, enabling coordinated studies with a global patient population.
The response to a genetically-targeted therapy can vary due to differences in ethnicity and environment. WIN's global studies are designed to identify and account for this variability, enhancing the speed and efficacy with which novel discoveries can be made and brought to patients around the world.

WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.
WIN prioritizes cross-sector interaction designed to enhance learning across and between continents and healthcare sectors.
WIN Symposia, held annually in Paris, bring together hundreds of leaders representing all stakeholders from around the world in a forum designed to promote the exchange of ideas and information.

Clinical trials and projects

WIN members collaboratively design and carry out global studies designed to achieve breakthroughs for patients worldwide. Our distinguished Scientific Advisory Board oversees WIN studies. Current trials include:

WINTHER, the WIN Consortium's first global personalized cancer medicine trial, is an ongoing global study carried out at multiple leading academic cancer centers around the world.
WINTHER aims to validate a breakthrough concept that would offer treatment guided by each patients biology for the vast majority of cancer patients.

With multiple cancer centers representing four countries - as well as partner biotech and pharma companies - WINTHER exemplifies WIN's commitment to innovative, collaborative studies that make effective, personalized medicine a reality for patients worldwide.
WIN is currently planning innovative global clinical trials that represent the next generation of studies focused on lung cancer.
European funded trials WINTHER EU FP7 funded and CHEMORES EU FP6 funded established foundations for WIN future global strategy for lung cancer currently under development.

The concept underlying the new strategy is developed in the following publications:
WIN provides a legal and fundraising framework that enables collective fundraising while protecting its members' intellectual property.
The WIN platform enables multiple organizations from different sectors to productively collaborate while providing for the protection of intellectual property. Each project or clinical trial has its own specific contract or funding mechanism.

People leadership

WIN leaders are selected for their contributions and commitment to making effective, personalized cancer medicine a reality for patients around the world. They guide WIN's strategic, operational, and scientific direction.

John Mendelsohn Photo
Chairman
John Mendelsohn

Director, Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA)

Richard L. Schilsky Photo
Chairman, WIN Scientific Advisory Board
Richard L. Schilsky

Chief Medical Officer, American Society of Clinical Oncology (ASCO); Chairman, WIN SAB

Razelle Kurzrock Photo
Chair, Clinical Trials Committee
Razelle Kurzrock

Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA)

Vladimir Lazar Photo
Chief Scientific and Operating Officer
Vladimir Lazar

Chief Scientific and Operating Officer, WIN Consortium


Our members

WIN members include 34 leading organizations representing all stakeholders in personalized cancer medicine. Our shared vision is delivering the promise of effective, personalized cancer medicine to patients worldwide.


WIN Symposia

WIN Symposia, held annually in Paris, gather leaders representing a breadth of stakeholders from around the world to learn, share, and collaborate. Visit http://www.winsymposium.org for registration and additional information.

WIN 2017 Symposium logotype

WIN 2017 Symposium

June 26, 2017 - June 27, 2017

The WIN Consortium will be holding its 9th Annual Symposium in Personalized Cancer Medicine in Paris, France, June 26-27, 2017. The overarching goal of our symposium is to share information to promote and accelerate cutting edge investigations and use of personalized, targeted cancer therapy.

WIN 2016 Symposium logotype

WIN 2016 Symposium

June 27, 2016 - June 28, 2016

The WIN 2016 Symposium “Innovative Approaches to Improve Cancer Patient Outcomes”, June 27-28th was the eighth in a series of symposia dedicated to advancing personalized cancer medicine. It was a successful unique forum that brought leaders representing all stakeholders - academia, pharma, biotech / life sciences, regulatory, and health payer - together from around the globe.

WIN 2015 Symposium logotype

WIN 2015 Symposium

June 29, 2015 - June 30, 2015

The WIN 2015 Symposium, on the theme of “Novel Targets, Innovative Agents, Advanced Technologies: A WINNing Strategy?” featured a global array of many of the world’s leading experts in personalized cancer medicine - from academia, pharma, biotech, and governmental organizations.


What people are saying


Dr. Vladimir Lazar named “Outstanding Chief Operating Officer of the Year” for 2016-2017
NEW YORK, NY - 06/06/2016 (PRESS RELEASE JET) — The International Society of Business Leaders, ISOBL, New York proudly announces the nomination of Dr. Vladimir Lazar as “Outstanding Chief Operating Officer of the Year”, in recognition for the creation of the WIN Consortium.

The International Society Of Business Leaders announces today the nomination of Dr. Vladimir Lazar as “Outstanding Chief Operating Officer of the Year 2016”. This nomination comes in recognition of the accomplishments in the field of biotechnology and life sciences following the creation of the Worldwide Innovative Networking in Cancer Precision Medicine, WIN Consortium, which today is undeniably a unique organization at the forefront of the fight against cancer.

Dr. Vladimir Lazar obtained his MD (1989) at The University of Timisoara (Romania), First in Class and Certificate of Merit “Magna cum Laudae”. He became a specialist in Clinical Biology (DIS, 1997, University René Descartes in Paris) and obtained his PhD in molecular biology (1997) at The University René Descartes in Paris, with the highest degree and the Prize of University. Dr. Vladimir Lazar is specialized in clinical biology, molecular biology, molecular pathology and has a broad training, education and postgraduate degrees in biotechnology (first in class) and project management. He is a recognized specialist in translating research into clinical applications. He was the founder and Head of Gustave Roussy’s Genomic Center and Integrated Biology Platform (2002-2015) running the Agilent European reference and training center. He is the founder and Chief Operating officer of the WIN Consortium. In these positions he has built a strong expertise in project design, technology evaluation and implementation, use of genomics and biomarkers in oncology, companion test development, and biology driven clinical trials. He is author of 6 patents and author-co-author of more than 100 publications.


In 2010, Dr. Lazar initiated the WIN Consortium in Cancer Precision Medicine. The primary motivation for founding this new organization was triggered by the refusal of the status quo of oncology today. Despite undeniable recent progress, with new promising drugs and new therapeutic avenues, a staggering number of cancer patients remain diagnosed in late metastatic stage. This is painfully true in the case of lung cancer, which is mostly diagnosed at metastatic stage and remains incurable, with a high burden for the society.


‘’With so many patients and families hit by cancer, waiting for effective treatments, siloed research gets in the way of innovation. With WIN Consortium, academics and industries are working together in order to shift the paradigm of cancer care. WIN was founded on the premise that we can accomplish more together than each organization can achieve working alone. In WIN, Academics and Industries work hand in hand to develop the tools and therapies needed to significantly improve survival and quality of life of cancer patients from diverse backgrounds.’’ said Dr. Vladimir Lazar.

WIN Consortium is a non-profit, non-governmental organization incorporated in France that assembles all stakeholders of cancer care. 33 members: 25 renowned academics in 14 countries and 4 continents, 2 patient advocates and 6 industries (technology and pharma). The organization is led by an Executive Committee of renown global experts in the field:


- John Mendelsohn, Chairman, Director of Khalifa Institute for Personalized Cancer Medicine and Past-President, the University of Texas MD Anderson Cancer Center (USA),
- Richard L. Schilsky, Chairman Scientific Advisory Board, Chief Medical Officer ASCO (USA),
- Razelle Kurzrock, Head of Clinical Trials Committee – Chief, Division of Hematology & Oncology, Sr. Deputy Center Director for Clinical Science, University of California San Diego Moores Cancer Center (USA),
- Vladimir Lazar, Founder and Chief Operating Officer (France)
- Catherine Bresson, Director of Operations (UK)

For more information on Dr. Lazar please contact him

Vladimir Lazar, +33-66-109-15-22
Vladimir.lazar@winconsortium.org
www.winconsortium.org
www.winsymposium.org
or
Institut Curie
+33-(0)1-56-24-55-00

Media Contacts:

Company Name: ISOBL
Full Name: STEPHANIE TAYLOR
Phone: 718 705 4936
Email Address: STAYLOR@ISOBL.COM
Website: WWW.ISOBL.COM
WIN is Very Proud to Announce That Institut Curie, France Has Joined Its Consortium
VILLEJUIF, France--(BUSINESS WIRE)--“We are very proud to welcome Institut Curie to WIN,” said Dr. John Mendelsohn, Chairman of WIN and Director of the Khalifa Institute for Personalized Cancer Therapy and past President of MD Anderson Cancer Center.“The Institut Curie is undeniably a leading European cancer research center with remarkable research that will constitute a major asset for WIN.”

WIN’s mission is to rapidly translate precision cancer medicine discoveries into standards of patient care worldwide. “Our vision and value proposition is that we can accomplish more together than each organization can achieve working alone. In WIN, renown academics and industries work hand in hand to develop the tools and therapies needed to significantly improve survival and quality of life of cancer patients from diverse backgrounds.” said Dr. Vladimir Lazar, Chief Operating Officer of WIN. WIN, through its network of academics, industries, insurance and patient advocates, is present in 14 countries and 4 continents. Not only it provides an effective platform to launch clinical trials but it is the place where transformational proof of concept trials paving the way for the future of cancer care can be developed, such as WINTHER, first trial of the WIN Consortium which was selected as a Success Story of the EUFP7.

WIN enables simultaneous access to patients with varied genetic backgrounds, enhancing the speed and efficacy with which novel discoveries can be made, in particular new biomarkers, and brought to patients around the world. Industry members contribute by developing the tools, to select the best therapies to treat patients: biological investigations of genes and gene products and algorithms.

“Precision cancer medicine remains very challenging, as the results of our SHIVA study prove. “ said Prof. Thierry Philip, President of Institut Curie. “We are thrilled to be able to present SHIVA and debate about the conclusions we can draw from the study at the WIN annual symposium on June 28-27 in Paris.”

"What SHIVA tells us is that we need to continue doing research in this area of personalized medicine,” said Dr. Richard L.Schilsky Chief Medical Officer of ASCO and chairman of WIN SAB.

Contacts
WIN
Vladimir Lazar, +33-66-109-15-22
Vladimir.lazar@winconsortium.org
www.winconsortium.org
www.winsymposium.org
or
Institut Curie
+33-(0)1-56-24-55-00
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium
The American Society of Clinical Oncology® Endorses the WIN 2016 Symposium: Innovative Approaches to Improve Cancer Patient Outcomes, June 27-28, 2016, Paris, France

VILLEJUIF, France--(BUSINESS WIRE)--The WIN Consortium (WIN) is proud to announce that its symposium dedicated to “Innovative approaches to improve cancer patient outcomes” has been endorsed by the American Society of Clinical Oncology (ASCO®) for its exceptional scientific program. “It is the 8th consecutive year that ASCO® has endorsed this unique scientific forum, that has become a major event in Precision Cancer Medicine”, said John Mendelsohn, Director for MD Anderson Institute for Personalized Cancer Therapy and Chairman of WIN.

WIN 2016’s symposium will be of exceptional value, as it will address very challenging and controversial themes. Precision medicine, as announced by the US President Barack Obama, has become a key objective shared by the oncology community. A special forum will be dedicated to discuss how to expedite precision cancer medicine with the outstanding participation of Bruce E. Johnson (ASCO® 2017 president elect), Richard L. Schilsky (ASCO®’s Chief Medical Officer and Chairman of WIN Scientific Advisory Board), Razelle Kurzrock (UCSD), William Sellers (Novartis), John Mendelsohn and many others.

The WIN symposium has increasingly become the forum where academia and industry share in a very candid way the latest innovations in cancer personalized medicine. But since there is no innovation without patients, this year, WIN2016 will present the opportunity for patient advocates to voice their opinions, in particular, Francesco de Lorenzo, the President of the European Cancer Patient Coalition (ECPC).

The greatest experts in the field of personalized and systems biology medicine in oncology will contribute to the program under the chairmanship of Dr. Josep Tabernero (Vall d’Hebron, Spain): Alberto Bardelli, Andrea Califano, Stephen Friend, Leroy Hood, Gordon B. Mills, and many others from academia, industry and cancer research organizations. They will present the latest innovations aiming at improving the survival and quality of life of cancer patients in the following sessions:

New tools for early diagnosis, selecting therapies and monitoring
Innovative clinical trials to substantially improve outcome
Relevant models and critical preclinical data before moving to the clinic
Translation of big data into clinical opportunities
The WIN 2016 symposium is the only event of its kind that enables all stakeholders of cancer care, from academia to industry, to present their latest advances.
For more information, take a look at www.winsymposium.org

This program is endorsed by ASCO®. ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. used with permission. This is not an ASCO® sponsored event.

Contacts
WIN Consortium
Vladimir Lazar
Chief Operating Officer
Vladimir.lazar@winconsortium.org
WIN will address the most critical question facing clinical cancer research: Why the improvement of survival still remains limited for most cancer patients? Save the date and register at: www.winsymposium.org
December 15, 2015 06:00 AM Eastern Standard Time

VILLEJUIF, France--(BUSINESS WIRE)--WIN 2016 will be held in Paris, France from 27-28 June 2016. It is the 8th edition of a successful series of symposia organized by the Worldwide Innovative Networking (WIN) Consortium, dedicated to advancing personalized cancer medicine through global collaboration.

This year WIN has chosen to address the critical question facing cancer research:
How innovative use of targeted therapies can improve survival of greater numbers of cancer patients?

Under the chairmanship of Dr. Josep Tabernero, (Vall d’ Hebron, Spain), the WIN Symposium will present a unique opportunity by bringing together a forum of world-class experts from different backgrounds including patient advocacies, academic and private research institutes and industry to address contemporary challenges and controversies around the next innovative steps in cancer therapy that will significantly improve patients’ outcomes.

Themes that will be addressed:
• Patients’ and advocacy perspectives
• New tools for early diagnosis, selecting therapies and monitoring
• Innovative clinical trials to substantially improve outcome
• Relevant models and critical preclinical data before moving to the clinic
• Translation of big data into clinical opportunities

“The annual symposium is the most visible part of the WIN Consortium’s activities, but perhaps the most exciting part of WIN is the engagement of all the different parties, from academic institutions to industry collaborators, and the unique opportunity this offers to truly collaborate in developing the next generation of clinical trials” John Mendelsohn, Chairman WIN Consortium, Director Khalifa Institute for Personalized Cancer Therapy, Past President, UT MDAnderson Cancer Center, USA.

WIN2016 Key dates

April 1, 2016 Early bird registration deadline

May 16, 2016 Abstract submission deadline

June 27-28, 2016
WIN 2016 Symposium

WIN 2016 will be happening around the UEFA European Football Championship (UEFA EURO 2016) in Paris. The delegates will have the opportunity to combine the best of science with this exceptional sports event. This will be a busy period, please book your travels in advance.

WIN2016 Venue
Novotel Paris Centre Eiffel Tower, 61 quai de Grenelle, Paris, France

About WIN:
A worldwide network assembling all cancer stakeholders to develop cutting edge concepts and clinical trials that improve survival for cancer patients.
WIN members include organizations representing all stakeholders in precision cancer medicine: cancer centers in 17 countries across 4 continents, major technology and pharmaceutical companies and institutes, patient advocacies, and health payers.

For information about WIN Consortium, its mission, vision, members and activities, please visit: www.winconsortium.org

Contacts
Catherine Bresson, +33 1 45 59 58 43

Director of WIN Operational Team
Catherine.bresson@winconsortium.org